New positive interim data in Phase 2 study of SNT-5505
Filed with ASX · · 5 pages · English
In the deck
Earlier from Syntara
- SNT-5505 awarded US FDA Fast Track designation
- Quarterly Activities Report
- Acceleration of skin scarring program
- Placement
- Equity Raising Presentation
Later from Syntara
- Quarterly Shareholder Report
- Quarterly Appendix 4C Cash Flow Report
- Suspension from Quotation
- Reinstatement to Quotation
- Guidance from FDA on amsulostat clinical progression
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara